BioSpace News Archive

Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.

Science 37 Holdings, Inc. today reported its financial results for the quarter and full year ended December 31, 2021.

Lantern Pharma Inc. announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern’s existing share repurchase program to acquire up to $7 million of the Company’s common stock.

Ecolab Inc. has increased its portfolio of Alliance for Water Stewardship (AWS) certified sites, adding two manufacturing plants in Lerma and Cuautitlan Izcalli, Mexico.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus, resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.

Webinar will be held on Wednesday, March 30, 2022 , from 8:00 a.m. to 9:00 a.m. EDT.

Calliditas Therapeutics AB announced that the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency can be expected in Q2, 2022.

BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a $22 million sale of equity in a non-brokered transaction.

Lung Therapeutics, Inc. announced the successful completion of a Phase 1a clinical trial for LTI-03, a Caveolin-1-related peptide designed to treat idiopathic pulmonary fibrosis.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2022 Conference on Thursday, March 24th at 01:00 p.m. Eastern Time.